Ralph Lippe
Overview
Explore the profile of Ralph Lippe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gordon K, Blauvelt A, Bachelez H, Coates L, Van den Bosch F, Kaplan B, et al.
Dermatol Ther (Heidelb)
. 2024 Aug;
14(9):2523-2538.
PMID: 39153059
Introduction: Risankizumab has demonstrated a favourable safety profile in patients with psoriatic disease (moderate-to-severe psoriasis [PsO] and psoriatic arthritis [PsA]). We evaluated the long-term safety of risankizumab in psoriatic disease....
2.
Kavanaugh A, Mease P, Gossec L, Ranza R, Tsuji S, Douglas K, et al.
ACR Open Rheumatol
. 2024 Aug;
6(11):736-745.
PMID: 39087872
Objective: We explored the relationship between achievement of clinical disease control and improvements in and normative values for patient-reported outcomes (PROs), including quality of life (QoL) measures, in patients with...
3.
Burmester G, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo V, Coombs D, et al.
Rheumatol Ther
. 2024 Apr;
11(3):737-753.
PMID: 38683479
Introduction: This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of...
4.
Kristensen L, Keiserman M, Papp K, McCasland L, White D, Carter K, et al.
Rheumatol Ther
. 2024 Mar;
11(3):617-632.
PMID: 38498141
Introduction: Patients with psoriatic arthritis (PsA) require treatment providing durable long-term efficacy in different disease domains as well as safety. We present 100-week efficacy and safety results of risankizumab in...
5.
Ostor A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, et al.
Rheumatol Ther
. 2024 Mar;
11(3):633-648.
PMID: 38498139
Introduction: Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who...
6.
Rubbert-Roth A, Kakehasi A, Takeuchi T, Schmalzing M, Palac H, Coombs D, et al.
Rheumatol Ther
. 2023 Nov;
11(1):97-112.
PMID: 37982966
Introduction: This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated with upadacitinib (UPA) or active...
7.
Charles-Schoeman C, Choy E, McInnes I, Mysler E, Nash P, Yamaoka K, et al.
RMD Open
. 2023 Nov;
9(4).
PMID: 37945286
Objectives: To provide an integrated analysis of major adverse cardiovascular events (MACEs) and events of venous thromboembolism (VTE) and associated risk factors across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and...
8.
Taylor P, Choy E, Baraliakos X, Szekanecz Z, Xavier R, Isaacs J, et al.
Rheumatology (Oxford)
. 2023 Aug;
63(2):298-308.
PMID: 37624925
Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction, including cytokines involved in a range of inflammatory diseases, such as RA, psoriasis, atopic dermatitis...
9.
McInnes I, Kato K, Magrey M, Merola J, Kishimoto M, Haaland D, et al.
Rheumatol Ther
. 2022 Oct;
10(1):275-292.
PMID: 36243812
Introduction: Efficacy and safety of the Janus kinase (JAK) inhibitor upadacitinib (UPA) was evaluated in patients with psoriatic arthritis (PsA) through week 104 of the ongoing long-term extension of the...
10.
Mease P, Kavanaugh A, Gladman D, FitzGerald O, Soriano E, Nash P, et al.
Rheumatol Ther
. 2022 May;
9(4):1181-1191.
PMID: 35606663
Introduction: Low disease activity (LDA)/remission is the target of treatment in patients with psoriatic arthritis (PsA). We assessed the proportions of patients with PsA receiving upadacitinib who achieved LDA/remission over...